Business Context and Reporting Period
KALA BIO, Inc. (Nasdaq: KALA), a Delaware corporation, filed a Current Report on Form 8-K dated January 8, 2026. The filing reports the entry into a material definitive agreement to establish an "at-the-market" (ATM) equity offering program.
Key Financial Metrics and Agreement Terms
- Offering Capacity: The aggregate market value of shares eligible for sale under the program is $15,000,000.
- Sales Agent: H.C. Wainwright & Co., LLC.
- Commission: The Company will pay a sales commission of 3.0% of the gross sales price of shares sold.
- Expense Reimbursement: The Company agreed to reimburse Wainwright up to $50,000 for legal fees and expenses, plus up to $3,500 per due diligence session update.
- Financial Performance: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a transactional report regarding a financing mechanism.
Material Changes and Outlook
The filing establishes a new mechanism for the Company to raise capital by selling common stock from time to time through Wainwright. Key operational details include:
- Flexibility: The Company retains the right to designate sale parameters, including share count, timing, daily limits, and minimum price thresholds.
- Discretion: The Company has no obligation to sell any shares, and either party may suspend offers at any time.
- Uncertainty: No assurance is given regarding the number of shares that will be sold, the price at which they will be sold, or the timing of such sales.
Investor Verification Checklist
- Verify the current share price and trading volume of KALA on Nasdaq to assess the potential dilution impact of a $15 million offering.
- Review the Company's most recent 10-K or 10-Q to determine current cash reserves and the urgency of this capital raise.
- Monitor future filings for actual sales activity under the ATM program, as no sales are guaranteed.
- Check for any concurrent announcements regarding clinical trial results or regulatory milestones that may influence the timing of share sales.